HIF1A and benign prostatic hyperplasia: found that VC effectively inhibited testosterone‐induced prostate cell proliferation, thereby preventing benign prostatic hyperplasia (BPH), a mechanism of action that involves inhibiting the expression and stabilisation of HIF‐1α [17].